Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 8 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Renal Metabolic

Heart Failure
TEER Linked to Better Outcomes in AFMR Patients
Added: 3 weeks ago Source:  Transcatheter Academy
A new study suggests that for elderly patients with atrial functional mitral regurgitation (AFMR), transcatheter edge-to-edge repair (TEER) is associated with a lower risk of mortality and heart failure hospitalisation compared with conventional medical therapy. The findings come from a propensity score-based comparison of two large Japanese registries, OCEAN-Mitral and REVEAL-AFMR… View more

Intervention

Demographic
Optimising RAASi Management in Cardiorenal Patients: An Expert Roundtable
Author(s): Andrew Frankel , Shelley Zieroth , Aaron Wong , et al Added: 1 year ago
In this on-demand version of the live roundtable, cardiologists Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA) and Dr Aaron Wong (Princess of Wales Hospital, Wales, UK) join nephrologists Dr Andrew Frankel (Imperial College Healthcare NHS Trust, London, UK), and Dr Manish Sood (University of Ottawa, CA) to discuss the nuanced landscape of RAASi management in cardiorenal patients.In… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ACC 24 Late-Breaker Discussion: The EMPACT-MI Trial
Author(s): Harriette Van Spall , Javed Butler Added: 2 years ago
ACC.24 — Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA), and Principal Investigator, Dr Javed Butler (University of Mississippi Medical Center, US), as they discuss the key findings from the EMPACT-MI trial (Boehringer Ingelheim)(NCT04509674).In this multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial, investigators evaluated the… View more

MI/ACS

Heart Failure
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
Author(s): Javed Butler , Dinesh Khullar , John JV McMurray , et al Added: 4 months ago
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He… View more

Prevention & Chronic Conditions

Heart Failure
THT 2025 Conference Announces its Late-Breaking Scientific Sessions
Added: 1 year ago Source:  THT
THT conference has released its four late-breaking trial sessions for 2025.The fourth annual Technology and Heart Failure Therapeutics conference is set to take place from the 11th to 13th February at Omni Boston Hotel at the Seaport in Boston. Access the full programme here.Late Breaking Clinical Science Session ITuesday 11th February, 09:30 – 10:45am ESTRobotic Surgical Technique for Performing… View more

Heart Failure
Medical Options for Advanced HFpEF/HFmrEF Patients
Author(s): Biykem Bozkurt , Muthiah Vaduganathan , Added: 1 year ago
Subtitles Available in:English, Français, Italiano, Español, Deutsch, 简体中文 and 日本語(click the icon in the video bar to select the subtitles).This video series is dedicated to tackling the complexities of managing HFpEF and HFmrEF patients, offering a comprehensive educational experience for healthcare professionals. Chairing the session, Dr Biykem Bozkurt (Baylor College of Medicine, US) is… View more

Heart Failure
Between the Sessions with Dr Parwani: VESALIUS-CV, KARDINAL, CHIP-BCIS3 & M
Author(s): Purvi Parwani Added: 2 weeks ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in… View more

Intervention

Prevention & Chronic Conditions
Executive Summary from the 2023 Charleston HFpEF Conference
Author(s): Sheldon E Litwin , Christian C Faaborg-Andersen , Ryan J Tedford Added: 1 year ago

Heart Failure
Author(s): Ambarish Pandey Added: 1 year ago
ACC 2025 - In this highlights video, Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:STRIDESOULFRESH-UPFAIR-HF 2Recorded on-site at ACC in Chicago, 2025.Support: This is an independent interview produced by Radcliffe… View more

Prevention & Chronic Conditions

Heart Failure